Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · Real-Time Price · USD
4.160
-0.190 (-4.37%)
At close: May 13, 2025, 4:00 PM
4.510
+0.350 (8.41%)
Pre-market: May 14, 2025, 8:51 AM EDT
Verve Therapeutics Employees
Verve Therapeutics had 274 employees as of December 31, 2024. The number of employees increased by 19 or 7.45% compared to the previous year.
Employees
274
Change (1Y)
19
Growth (1Y)
7.45%
Revenue / Employee
$217,566
Profits / Employee
-$660,606
Market Cap
370.84M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 274 | 19 | 7.45% |
| Dec 31, 2023 | 255 | 51 | 25.00% |
| Dec 31, 2022 | 204 | 91 | 80.53% |
| Dec 31, 2021 | 113 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VERV News
- 11 days ago - Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy' - Seeking Alpha
- 4 weeks ago - Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose - Benzinga
- 4 weeks ago - Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 - GlobeNewsWire
- 4 weeks ago - Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 - GlobeNewsWire
- 7 weeks ago - Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose - GlobeNewsWire
- 2 months ago - Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 3 months ago - Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm - PRNewsWire